Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma

European Journal of Clinical Investigation

Volumn 42, Issue 9, 2012, Pages 953-960

  Atamaniuk, Johanna ^a   Gleiss, Andreas ^a   Porpaczy, Edit ^a   Kainz, Birgit ^a   Grunt, Thomas W ^a   Raderer, Markus ^a   Hilgarth, Bernadette ^a   Drach, Johannes ^a   Ludwig, Heinz ^b   Gisslinger, Heinz ^a   Jaeger, Ulrich ^a   Gaiger, Alexander ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

Author keywords

Bone marrow; Cytogenetics; GPRC5D mRNA expression; Multiple myeloma

Indexed keywords

BETA 2 MICROGLOBULIN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 5D; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER SURVIVAL; CHROMOSOME 13Q; CHROMOSOME 14Q; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 4; CLINICAL ARTICLE; FEMALE; GENE OVEREXPRESSION; HUMAN; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CYTOGENETICS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, G-PROTEIN-COUPLED; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, MESSENGER; STATISTICS AS TOPIC; TRANSLOCATION, GENETIC;

EID: 84865177367     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02679.x     Document Type: Article

References (24)

1. Blade J, Rosinol L. Changing paradigms in the treatment of multiple myeloma. Haematologica 2009;94:163-6.
2. Harousseau JL. Induction therapy in multiple myeloma. Hematology Am Soc Hematol Educ Program 2008;1:306-12.
3. Blade J, Rosinol L. Advances in therapy of multiple myeloma. Curr Opin Oncol 2008;20:697-704.
4. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009;374:324-39.
5. Kettle JK, Finkbiner KL, Klenke SE, Baker RD, Henry DW, Williams CB. Initial therapy in multiple myeloma: investigating the new treatment paradigm. J Oncol Pharm Pract 2009;10:10.
6. Berenson JR, Yellin O. New drugs in multiple myeloma. Curr Opin Support Palliat Care 2008;2:204-10.
7. Podar K, Tai YT, Hideshima T, Vallet S, Richardson PG, Anderson KC. Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs 2009;14:99-127.
8. Maiso P, Ocio EM, Garayoa M, Montero JC, Hofmann F, Garcia-Echeverria C et al. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br J Haematol 2008;141:470-82.
9. Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov 2009;4:54-72.
10. Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernandez S, San-Segundo L et al. Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood 2009;113:3781-91.
11. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9.
12. Heintel D, Zojer N, Schreder M, Strasser-Weippl K, Kainz B, Vesely M et al. Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia 2008;22:441-5.
13. Brauner-Osborne H, Jensen AA, Sheppard PO, Brodin B, Krogsgaard-Larsen P, O'Hara P. Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D. Biochim Biophys Acta 2001;1518:237-48.
14. Inoue S, Nambu T, Shimomura T. The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J Invest Dermatol 2004;122:565-73.
15. Xu J, Tian J, Shapiro SD. Normal lung development in RAIG1-deficient mice despite unique lung epithelium-specific expression. Am J Respir Cell Mol Biol 2005;32:381-7.
16. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
17. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343-6.
18. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
19. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009;114:518-21.
20. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210-21.
21. Feller D, Cruz VF. Identifying antigenic T cell sites. Nature 1991;349:720-1.
22. Rothbard JB, Taylor WR. A sequence pattern common to T cell epitopes. EMBO J 1988;7:93-100.
23. Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009;10:10.
24. Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 2009;9:278-88.